6-chloro-2-(pyrazol-1-yl)pyrimidin-4-amine | 1032050-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-chloro-2-(pyrazol-1-yl)pyrimidin-4-amine
• 英文别名: 6-Chloro-2-pyrazol-1-ylpyrimidin-4-amine
• CAS: 1032050-69-3
• 化学式: C₇H₆ClN₅
• 分子量: 195.611
• InChiKey: QAPGKFODADBGKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-chloro-2-(pyrazol-1-yl)pyrimidin-4-amine 、 乙酸酐 以 溶剂黄146 为溶剂， 生成 N-(6-chloro-2-pyrazol-1-ylpyrimidin-4-yl)acetamide
  参考文献：
  名称：

  N-[6-Amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A_2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy

  摘要：

  In the present article, we report on a strategy to improve the physical properties of a series of small molecule human adenosine 2A (hA(2A)) antagonists. One of the aromatic rings typical of this series of antagonists is replaced with a series of aliphatic groups, with the aim of disrupting crystal packing of the molecule to lower the melting point and in turn to improve the solubility. Herein, we describe the SAR of a new series of water-soluble 2,4,6-trisubstituted pyrimidines where R-1 is an aromatic heterocycle, R-2 is a short-chain alkyl amide, and the typical R-3 aromatic heterocyclic substituent is replaced with an aliphatic amino substituent. This approach significantly enhanced aqueous solubility and lowered the log P of the system to provide molecules without significant hERG or CYP liabilities and robust in vivo efficacy.

  DOI：

  10.1021/jm800908d
• 作为产物：
  描述：

  吡唑 、 4-氨基-2,6-二氯嘧啶 在 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 72.0h， 以39%的产率得到6-chloro-2-(pyrazol-1-yl)pyrimidin-4-amine
  参考文献：
  名称：

  WO2008/70661

  摘要：

  公开号：

文献信息

• SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Lanier Marion

  公开号：US20100234341A1

  公开（公告）日：2010-09-16

  Compounds of formula (I) including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  公式（I）的化合物，包括药学上可接受的盐、酯、溶剂和立体异构体，其中R1、R2和R3的定义如本文所述。本发明还公开了含有结构（I）化合物的制药组合物，以及与其使用相关的方法。
• WO2008/70661
  申请人：——

  公开号：——

  公开（公告）日：——
• <i>N</i>-[6-Amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A_2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy
  作者：Marion C. Lanier、Manisha Moorjani、Zhiyong Luo、Yongsheng Chen、Emily Lin、John E. Tellew、Xiaohu Zhang、John P. Williams、Raymond S. Gross、Sandra M. Lechner、Stacy Markison、Tanya Joswig、William Kargo、Jaime Piercey、Mark Santos、Siobhan Malany、Marilyn Zhao、Robert Petroski、María I. Crespo、José-Luis Díaz、John Saunders、Jenny Wen、Zhihong O’Brien、Kayvon Jalali、Ajay Madan、Deborah H. Slee

  DOI：10.1021/jm800908d

  日期：2009.2.12

  In the present article, we report on a strategy to improve the physical properties of a series of small molecule human adenosine 2A (hA(2A)) antagonists. One of the aromatic rings typical of this series of antagonists is replaced with a series of aliphatic groups, with the aim of disrupting crystal packing of the molecule to lower the melting point and in turn to improve the solubility. Herein, we describe the SAR of a new series of water-soluble 2,4,6-trisubstituted pyrimidines where R-1 is an aromatic heterocycle, R-2 is a short-chain alkyl amide, and the typical R-3 aromatic heterocyclic substituent is replaced with an aliphatic amino substituent. This approach significantly enhanced aqueous solubility and lowered the log P of the system to provide molecules without significant hERG or CYP liabilities and robust in vivo efficacy.